^
Association details:
| Biomarker: | PPP2R2B underexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Published date:
11/18/2020
Excerpt:
...we took advantage of a phase II clinical trial patient cohort comprises of non-metastatic HER2+ patients treated with neoadjuvant lapatinib, an HER2 kinase inhibitor, plus chemotherapy (paclitaxel and carboplatin)...We found that tumors with lower levels of PPP2R2B expression showed significantly less size reduction after two cycles of neoadjuvant treatment compared to tumors with higher expression of PPP2R2B (P = 0.0080...
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1038/s41467-020-19704-x
Trial ID: